Alpha-fetoprotein acts as a key regulator of cancer stemness in hepatocellular carcinoma via PI3K/Akt pathway
Cellular Signalling · 2026-06 · 142 · 112401
DOI: 10.1016/j.cellsig.2026.112401 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026-06. Verfasst von Gulijiamali Kahaer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Tropical Translational Medicine of Ministry of Education & Hainan Provincial Key Laboratory of Carcinogenesis and Intervention, Sch…. Hauptthemen laut MEDLINE: alpha-Fetoproteins, Proto-Oncogene Proteins c-akt, Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Hainan Province Natural Science Foundation, Hainan Medical University, Key Research and Development Project of Hainan Province.
Abstract (Originalsprache)
Alpha-fetoprotein (AFP) is a well-established diagnostic biomarker for hepatocellular carcinoma (HCC), yet its functional role in tumor progression extends far beyond serological detection. Specifically, its ability to regulate cancer stemness, a key driver of therapy resistance and recurrence, remains largely unexplored. Here, we demonstrate that AFP is a critical functional regulator of cancer stem-like cells (CSC) in HCC. In this study, we employed CRISPR/Cas9-mediated gene editing to generate AFP-knockout models in Huh7 and PLC/PRF/5 cell lines, enabling a systematic investigation of AFP's oncogenic functions. Comparative analyses demonstrated that AFP ablation markedly reduced tumorigenic potential in vivo, accompanied by downregulation of stemness markers (EPCAM and CD44) and inhibition of PI3K/Akt signaling. Mechanistic studies further identified the PI3K/Akt pathway as critical for AFP-mediated maintenance of cancer stem cell properties. Collectively, our findings provide direct evidence that AFP-driven stemness contributes functionally to HCC progression, establishing AFP as a molecular regulator rather than merely a diagnostic marker. This study elucidates a novel AFP-PI3K/Akt-stemness axis in HCC pathogenesis and highlights potential therapeutic targets for stemness-directed interventions in AFP-positive HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Tropical Translational Medicine of Ministry of Education & Hainan Provincial Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine, Hainan Medical University, Haikou 571199, Haina…
Förderung
- Hainan Province Natural Science Foundation
- Hainan Medical University
- Key Research and Development Project of Hainan Province
Zitieren
APA
Kahaer, G., Pan, S., Xie, W., Li, Y., Yang, C., Zhang, X., Wang, H., & Lu, Y. (2026). Alpha-fetoprotein acts as a key regulator of cancer stemness in hepatocellular carcinoma via PI3K/Akt pathway. Cellular Signalling, 142, 112401. https://doi.org/10.1016/j.cellsig.2026.112401
Vancouver
Kahaer G, Pan S, Xie W, Li Y, Yang C, Zhang X, et al. Alpha-fetoprotein acts as a key regulator of cancer stemness in hepatocellular carcinoma via PI3K/Akt pathway. Cellular Signalling. 2026;142:112401. doi:10.1016/j.cellsig.2026.112401
BibTeX
@article{Kahaer2026,
author = {Kahaer, Gulijiamali and Pan, Sirun and Xie, Wenchen and Li, Yue and Yang, Chengcheng and Zhang, Xin and Wang, Han and Lu, Yan},
title = {Alpha-fetoprotein acts as a key regulator of cancer stemness in hepatocellular carcinoma via PI3K/Akt pathway},
journal = {Cellular Signalling},
year = {2026},
volume = {142},
pages = {112401},
doi = {10.1016/j.cellsig.2026.112401}
}
EUVIMED